scholarly journals Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: A report from the children's oncology group

2013 ◽  
Vol 134 (2) ◽  
pp. 431-436 ◽  
Author(s):  
Philip J. Lupo ◽  
Renke Zhou ◽  
Stephen X. Skapek ◽  
Douglas S. Hawkins ◽  
Logan G. Spector ◽  
...  
Keyword(s):  
Oncology Group ◽  
Related Factors ◽  
Childhood Rhabdomyosarcoma

scholarly journals Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group

2014 ◽  
Vol 25 (7) ◽  
pp. 905-913 ◽  
Author(s):  
Philip J. Lupo ◽  
Heather E. Danysh ◽  
Stephen X. Skapek ◽  
Douglas S. Hawkins ◽  
Logan G. Spector ◽  
...  
Keyword(s):  
Oncology Group ◽  
Birth Characteristics ◽  
Childhood Rhabdomyosarcoma

scholarly journals The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group

2016 ◽  
Vol 63 (9) ◽  
pp. 1557-1562 ◽  
Author(s):  
Hari Sankaran ◽  
Heather E. Danysh ◽  
Michael E. Scheurer ◽  
M. Fatih Okcu ◽  
Stephen X. Skapek ◽  
...  
Keyword(s):  
Oncology Group ◽  
Childhood Infections ◽  
Childhood Rhabdomyosarcoma

scholarly journals The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group

2021 ◽  
Vol 143 ◽  
pp. 127-133
Author(s):  
Archana Shenoy ◽  
Elysia Alvarez ◽  
Yueh-Yun Chi ◽  
Minjie Li ◽  
Jack F. Shern ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Oncology Group ◽  
Childhood Rhabdomyosarcoma

scholarly journals Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

2016 ◽  
Vol 34 (25) ◽  
pp. 3014-3022 ◽  
Author(s):  
Dawn L. Hershman ◽  
Cathee Till ◽  
Jason D. Wright ◽  
Danielle Awad ◽  
Scott D. Ramsey ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Autoimmune Disease ◽  
Oncology Group ◽  
Related Factors ◽  
Southwest Oncology Group ◽  
Varicella Zoster ◽  
Platinum Agent ◽  
History Of ◽  
Clinical Records ◽  
Phase Ii And Iii

Background Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy. Methods We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy. Results A total of 1,401 patients from 23 studies were included in the analysis. Patients receiving paclitaxel were more likely to experience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.52 to 3.18; P < .001). The inclusion of a platinum agent was also associated with greater neuropathy (OR, 1.68; 95% CI, 1.18 to 2.40; P = .004). For each increase in age of 1 year, the odds of neuropathy increased 4% (P = .006). Patients with complications from diabetes had more than twice the odds of having neuropathy (OR, 2.13; 95% CI, 1.31 to 3.46; P = .002) compared with patients with no diabetes. In contrast, patients with autoimmune disease were half as likely to experience neuropathy (OR, 0.49; 95% CI, 0.24 to 1.02; P = .06). The other conditions were not associated with neuropathy. Conclusion We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist.

scholarly journals Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

2019 ◽  
Vol 8 (14) ◽  
pp. 6437-6448 ◽  
Author(s):  
Emily Hibbitts ◽  
Yueh‐Yun Chi ◽  
Douglas S. Hawkins ◽  
Frederic G. Barr ◽  
Julie A. Bradley ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Risk Stratification ◽  
Outcome Predictors ◽  
Oncology Group ◽  
Childhood Rhabdomyosarcoma

scholarly journals Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database

2015 ◽  
Vol 4 (5) ◽  
pp. 781-790 ◽  
Author(s):  
Philip J. Lupo ◽  
Heather E. Danysh ◽  
Sharon E. Plon ◽  
Karen Curtin ◽  
David Malkin ◽  
...  
Keyword(s):  
Family History ◽  
Oncology Group ◽  
Population Database ◽  
Family History Of Cancer ◽  
History Of ◽  
Childhood Rhabdomyosarcoma ◽  
History Of Cancer
Sign in / Sign up

Export Citation Format

Share Document